IP Library Granted Patent US 8,871,487
Granted Patent B2
US 8,871,487 · App. 12/631,629 · Granted Oct 28, 2014

Compositions, methods and uses for inducing viral growth

Inventors: Dan T. Stinchcomb (Fort Collins, CO); Jill A. Livengood (Fort Collins, CO); O'Neil Wiggan (Fort Collins, CO); Richard Kinney (Fort Collins, CO); Jorge Osorio (Mount Horeb, WI)
Assignee: Takeda Vaccines, Inc.
C12N7/00C12N2770/24151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,871,487
App. No.
12/631,629
Granted
Oct 28, 2014
Kind
B2
Abstract

Embodiments herein report methods, compositions and uses for inducing and/or accelerating viral growth. In certain embodiments, methods, compositions and uses generally related to copolymer compositions for inducing viral growth, reducing lag time and/or increasing viral plaque size. In other embodiments, methods, compositions and uses of copolymer compositions can be for inducing flaviviral growth, reducing lag in growth and/or increasing plaque size.

Claims (37)

1. A composition for growing viral cultures comprising:

one or more ethylene oxide propylene oxide (EO-PO) block copolymers, the EO-PO block copolymers comprise poloxamer 407 , poloxamer 403 or a combination thereof wherein the concentration of EO-PO block copolymer is from 0.063% to 3.0%;

a viral culture;

a host cell; and

a media for growing the viral cultures,

wherein the EO-PO block copolymers accelerate growth of viral cultures.

2. The composition of claim 1 , wherein the viral cultures are selected from the group consisting of Flavivirus, Togavirus, Coronavirus, Filovirus, Paramyxovirus, Orthomyxovirus, Bunyavirus, Arenavirus, Retrovirus, Hepadnavirus, Pestivirus, Herpes virus, and Poxvirus.

3. The composition of claim 1 , wherein the viral cultures are Flavivirus cultures.

4. The composition of claim 1 , wherein the viral cultures are Poxvirus cultures.

5. The composition of claim 1 , wherein at least one of the one or more ethylene oxide propylene oxide (EO-PO) block copolymers comprises poloxamer 407 and the media comprises Dulbecco's Modified Eagle Medium (DMEM).

6. A method for increasing viral growth rate comprising, administering to a host cell culture infected with a virus, a composition comprising one or more ethylene oxide propylene oxide (EO-PO) block copolymers , the EO-PO block copolymers comprise poloxamer 407 , poloxamer 403 or a combination thereof wherein the concentration of EO-PO block copolymer is from 0.063% to 3.0% and a viral growth media, wherein the composition increases viral growth rate in the culture.

7. A method for increasing viral growth rate comprising, administering a composition comprising one or more ethylene oxide propylene oxide (EO-PO) block copolymers to a host cell culture, before, during, or after viral infection of the host cell culture and increasing viral growth rate in the host cell culture, wherein the EO-PO block copolymers comprise poloxamer 407 , poloxamer 403 or a combination thereof wherein the concentration of EO-PO block copolymer is from 0.063% to 3.0%.

8. A method for increasing plaque size of a viral culture comprising, administering to a host cell culture infected with a virus, a composition comprising one or more ethylene oxide propylene oxide (EO-PO) block copolymers wherein the composition increases viral plaque size in the host cell culture compared to a control viral culture without administering one or more ethylene oxide propylene oxide (EO-PO) block copolymers, wherein the EO-PO block copolymers comprise poloxamer 407 , poloxamer 403 or a combination thereof wherein the concentration of EO-PO block copolymer is from 0.063% to 3.0%.

9. A method for reducing growth lag time of a viral culture comprising, administering to a host cell culture infected with a virus, a composition comprising one or more ethylene oxide propylene oxide (EO-PO) block copolymers wherein the composition reduces lag time of the viral cultures in the host cell culture compared to a control viral culture without administering one or more ethylene oxide propylene oxide (EO-PO) block copolymers, wherein the EO-PO block copolymers comprise poloxamer 407 , poloxamer 403 or a combination thereof wherein the concentration of EO-PO block copolymer is from 0.063% to 3.0%.

10. The method of claim 9 , wherein the viral cultures are selected from Flaviviral cultures.

11. The method of claim 9 , wherein the viral cultures comprise viral cultures for generating live, attenuated viral vaccines.

12. The method of claim 9 , wherein the reduction in lag time comprises at least a 10 percent reduction in lag time compared to viral cultures without one or more ethylene oxide propylene oxide (EO-PO) block copolymers.

13. A kit for culturing viruses comprising;

at least one container; and

a composition comprising the composition of claim 1 .

14. The kit of claim 13 , wherein the viral culture are one or more Flaviviruses.

15. The kit of claim 13 , further comprising a host cell stock culture comprising Vero (African green monkey Vero cells), LLC-MK2 cells (monkey kidney cells), or C6/36 mosquito cells.

16. The composition of claim 1 , wherein the virus comprises Flavivirus and the host cell culture comprises Vero (African green monkey Vero cells), LLC-MK2 cells (monkey kidney cells), or C6/36 mosquito cells.

17. A composition for growing viral cultures comprising:

an ethylene oxide propylene oxide (EO-PO) block copolymer comprising poloxamer 403 , at a concentration range of 0.063% to 3.0%;

a viral culture;

a host cell; and

a media for growing the viral cultures,

wherein the EO-PO block copolymer induces growth of viral cultures, wherein the host cells are grown to confluence.

18. The composition of claim 17 , further comprising_poloxamer 407 .

19. A composition for growing viral cultures comprising:

one or more ethylene oxide propylene oxide (EO-PO) block copolymers, the EO-PO block copolymers are selected from the group consisting of poloxamer 407 , poloxamer 403 , and a combination thereof wherein the concentration of EO-PO block copolymer is about 0.063% to 3.0%;

a viral culture;

a host cell; and

a media for growing the viral cultures,

wherein the EO-PO block copolymers accelerate growth of viral cultures, wherein the host cells are grown to confluence.

20. The composition of claim 19 , wherein the viral culture titer is from about 1×10 6 pfu/mL to about 1×10 9 pfu/mL.

Assignments (4)
ASSIGNEE CHANGE OF ADDRESS RECORDED ON REEL 033575 FRAME 0662 Recorded Sep 22, 2023
From: TAKEDA VACCINES INC.
To: TAKEDA VACCINES INC.
Reel/Frame 065020/0869 →
CONFIRMATORY LICENSE Recorded Nov 24, 2015
From: INVIRAGEN, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 037155/0249 →
MERGER AND CHANGE OF NAME Recorded Aug 20, 2014
From: INVIRAGEN, INC.; TAKEDA VACCINES (MONTANA), INC.; TAKEDA VACCINES, INC.
To: TAKEDA VACCINES, INC.
Reel/Frame 033575/0662 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 1, 2010
From: STINCHCOMB, DAN T.; LIVINGOOD, JILL A.; WIGGAN, O'NEIL; KINNEY, RICHARD; OSORIO, JORGE
To: INVIRAGEN, INC.
Reel/Frame 024008/0789 →
Continuity (2)
Provisional Application 61120262 · Dec 5, 2008
Related Publication 20100144015A1 · Jun 10, 2010